Want to join the conversation?
Shannon Cross of Cross Research asks for an update on currency from the Doc Tech perspective. $XRX said in 2Q16, it saw equipment price pressures at the low end of the 5-10% range. The segment margin pressure was modest in 2Q16 versus 1Q16. The company has currency risk-sharing agreements and hedging in place to mitigate impacts from the yen.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.